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COMPARING GENE THERAPY WITH CURRENT STANDARDS OF 
TREATMENT 
ERICK MARTIN OTINIANO 
ABSTRACT 
  Gene therapy holds a significant promise of bettering the treatment modality. 
Gene therapy offers the potential of lifetime cure. Suffering patients become 
asymptomatic with the respective disorder when gene therapy is administered. However, 
there exists an underlying issue on the matter concerning long term effects and the high 
cost associated with gene therapy.  This study is meant to overview the benefits and 
safety associated with gene therapy and compare it with the standard ways of treating 
patients suffering from genetic disorders. The study will offer a comprehensive resource 
on the available evidence of future and ongoing trials and research. 
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INTRODUCTION 
 There are genetic disorders that have monumental impacts on the health and 
quality of life of those affected. Current methods of treatment, however, are challenging, 
expensive, and require constant administration. In recent times, gene therapy has been 
incorporated in the treatment strategies for complex genetic disorders. This literature 
review describes the history of gene editing and gene therapy, presents a detailed 
overview of the CRISPR/Cas9 system, and analyzes current applications of gene therapy. 
 
Specific Objectives 
Specific aims of this thesis: 
1. To compare and understand different types of gene therapy and understand the 
extent to which they compare with the current standard forms of treatment.  
2. To understand the extent to which gene therapy hold the significant the 
promise of substantially and bettering treatment modality. 
3. To understand the implications associated with utilizing gene therapy. 
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BACKGROUND 
History of Gene Therapy 
Several critical discoveries facilitated the development of gene therapy. In 1928, 
Frederick Griffith, described the transformation of a non-virulent pneumococcal type to a 
virulent type in his experimentation with bacterial pneumonia and mice (Griffith 1928). 
The research was further investigated through the disruption of various forms of 
pneumococcus, through the release and filtering of the intracellular content, and the 
subsequent "transformation" of an R form of pneumococcus when adding the filtered 
cell-free extract (Alloway 1932). Alloway’s experiment showcased that there was 
something that was causing the transformation. In 1944, Avery et al discovered that the 
transformation was caused by deoxyribonucleic acid (DNA) (Avery, MacLeod, and 
McCarty 1944). 
Transduction was discovered in 1952. Zinder and Lederberg found that 
recombination between different types of salmonella occurred through an active filtrate 
that transferred, or transduced, hereditary traits between bacterial strains (Zinder and 
Lederberg 1952). This discovery was pivotal because it described how different species 
of bacteria achieved antibiotic resistance quickly. The ability to transfer genetic material 
became of interest for scientists aiming to utilize this ability to benefit eukaryotes. 
Waclaw Szybalski was successful in demonstrating heritable transformation of a 
biochemical trait (Szybalska and Szybalski 1962). Szybalski isolated phenotypes of cells 
by focusing on biochemical pathways. Szybalski extracted cells that either contained or 
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were deficient of hypoxanthine-guanine phosphoribosyl transferase (HGPRT), a 
transferase critical to the salvage pathway. He then used a specific medium to force cells 
to utilize an alternative salvage pathway to create nucleic acids. Szybalski rescued the 
HGPRT(-) cells by transferring functional DNA from HGRPT(+) cells. He also showed that 
a rescued gene could be inherited, the first documented evidence of heritable gene 
transfer in mammalian cells. 
In 1961, the traditional rationale that genetic information could only flow from 
DNA to RNA was eliminated. Howard Temin observed that chicken cells infected with 
the Rous sarcoma virus (RSV) stably inherited viral genes to generate RSV progeny 
(Temin 1961). This subsequently led to the discovery of RNA-dependent DNA 
polymerase. 
The notion that viruses had ideal properties to deliver genes to cells of interest 
garnered further interest in gene therapy with several experiments and attempts occurring 
for some time, however, there were concerns with safety and efficacy (Temin 1961). The 
first approved clinical protocol introducing foreign genes in to humans was no actual 
therapy, but instead used for gene marking purposes to track tumor infiltrating blood cells 
in cancer patients (S. Rogers and Pfuderer 1968).  
The first trial conducted using a therapeutic gene aimed to help two children 
suffering from adenosine deaminase deficiency (ADA-SCID), a monogenetic disease 
leading to severe immunodeficiency (Stanfield Rogers et al. 1973). White blood cells 
extracted from the blood of the patients were modified ex vivo to express the normal 
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gene for making adenosine deaminase. There were unclear results of the efficacy of the 
gene therapy in this study, however, various other gene therapy studies began. The boom 
of gene therapy studies continued until the tragic death of Jesse Gelsinger, a patient in a 
gene therapy clinical trial that died from multiorgan failure caused by an adverse immune 
response to gene therapy (Stolberg 1999).   
History of Gene Editing 
The discovery of the ability to utilize homologous recombination to exchange 
endogenous genomic sequences for exogenous sequences was critical in developing gene 
targeting methodologies (Smithies et al. 1984). Quickly after that, it was noted that 
opening the donor DNA molecule through a double-strand break within the specified 
region of homology significantly improved the frequency of homologous recombination 
within a gene (Kucherlapati et al. 1984). This was instrumental in forming the first gene 
editing strategies. 
 The next discovery was instrumental in framing gene editing. Besides, the ability 
of I-SceI meganuclease to promote homologous recombination in chromosomes was 
recognized for promoting homologous recombination two times more than spontaneous 
homologous recombination (Jacquier and Dujon 1985; Choulika et al. 1995). Despite this 
great discovery, several limitations on production and other mammalian applications led 
to more focus on other gene editing methods (Pan et al. 2006). 
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Zinc-finger nucleases (ZFN) 
ZFN was developed when the first chimeric proteins were shown to effectively 
cleave and promote homologous recombination at specific locations in the genome of 
Xenopus embryos (Bibikova et al., 2001). ZFNs continued to be improved as they were 
shown to correct mutations in cells through homologous recombination (Urnov et al., 
2005). 
 ZFN was quickly transformed for application of gene editing in mammals. ZFN 
was used to create the first knockout rats (Geurts et al., 2009). The use of ZFN became 
widespread and was used successfully in gene editing experiments in mice, cattle, and 
pigs (Carbery et al., 2010; Carlson et al., 2012; Yu et al., 2011). Many of these studies led 
to the usage of various approaches of gene editing to treat livestock, which currently have 
increased the resistance of animals to multiple diseases (Lillico et al. 2016). ZFN was 
also explored for gene therapy purposes. However, some limitations of this type of gene 
editing have showcased to have some bottlenecks. ZFN has been observed to have 
minimal sequence specificity and can often develop off-target edits (Radecke et al. 2010). 
Transcription activator-like effector nucleases (TALEN).  
TALENs had a very similar history to ZFN. TALENs were used to produce 
knockout rats (Tesson et al., 2011). TALENs were also used in mice and several species 
of livestock (Carlson et al., 2012; Panda et al., 2013). Some of the benefits of gene 
editing using TALEN included the creation of cattle with increased resistance to 
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tuberculosis (Wu et al., 2015). However, TALENs differs from ZFNs in that they are not 
proprietary and easy to prepare in local labs (Mussolino & Cathomen, 2012). 
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR 
associated proteins (Cas) 
 CRISPR/Cas9 was discovered as an efficient and easy way to edit genes in 2012 
by at least 2 groups (Gasiunas et al. 2012; Jinek et al. 2012). CRISPR/Cas9 were found as 
part of an adaptive immune system of a prokaryote and in turn became utilized for gene 
editing. The CRISPR/Cas9 system derives from a bacterial type well referred to as Type 
II CRISPR adaptive immune system. 
 CRISPR requires two main components. The first is a small molecule of RNA, 
responsible for pairing with the corresponding homologous DNA sequence at the target 
site. The second is a DNA endonuclease that cleaves the DNA and generates the unique 
double strand break at the locus of choice, driven by a short RNA molecule. CRISPR 
systems utilize their own natural endonucleases, Cas9 for example, making 
CRISPR/Cas9 systems easier to access, than ZFNs and TALENs. Additionally, as 
CRISPR systems rely on RNA-DNA interaction as opposed to the less stable protein-
DNA interactions of ZFNs and TALENs (Seruggia and Montoliu 2014). 
 CRISPR has become a preferred method of gene editing for its efficiency, low 
cost, and ease of use (Harms et al. 2014). This study will further focus on CRISPR/Cas9 
systems and its application of gene therapy. 
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THE BASICS OF GENE THERAPY 
Gene therapy types  
Gene therapy is the active process of introducing DNA into a patient to treat or 
prevent diseases associated with genetic disorders (“What Is Gene Therapy?” 2016). The 
new DNA is carefully selected and generally contains a functioning gene to correct the 
effects of a disease-causing mutation. There are two types of gene therapy: 
1. Somatic gene therapy – the transfer of a specific section of DNA to any somatic 
cells, or cells that do not produce sperm or eggs. The effects of these therapies are 
not inheritable by offspring. 
2. Germline gene therapy – the transfer of a specific section of DNA to any germ 
cells, or cells that produce sperm or eggs. The effects of these therapies are 
inherited by offspring. 
Gene therapy techniques 
There are several techniques to carry out gene therapy: 
1. Gene augmentation therapy – treatment used to treat diseases that stop a cell from 
properly producing a functional product, such as a protein. The new gene 
produces a functioning product and physiological sufficient levels. 
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Figure 1 – Gene Augmentation Therapy. Cell receives a functioning gene and 
returns to normal function (“What Is Gene Therapy?” 2016).  
 
2. Gene inhibition therapy – treatment for inappropriately active genes. In this 
treatment, a gene is introduced that inhibits the expression of another gene and/or 
interferes with the activity of the product of another gene. 
 
Figure 2 – Gene Inhibition Therapy. Cell receives a gene to inhibit abnormal 
function, returning the cell to normal function (“What Is Gene Therapy?” 2016). 
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3. Specific cell elimination – treatment for diseases that can be terminated by killing a 
particular group of cells by inserting DNA in to diseased cells to prompt death. This 
can be achieved by either inserting DNA that contains genes to produce self-lethal 
products or by inserting DNA that causes the expression or a protein that marks the 
diseased cell for elimination by the immune system. It is crucial with this technique 
that the inserted DNA be targeted accurately and precisely to avoid affecting non-
diseased cells. 
 
Figure 3 – Specific Cell Elimination. Abnormal cells can be eliminated via 2 
methods within gene therapy. The first method utilizes a suicide gene to make the 
abnormal cell generate toxic substances and destroy itself (top of figure). The 
second method utilizes a marker gene to make the abnormal cell mark itself for 
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destruction by the organism’s immune system (bottom of figure) (“What Is Gene 
Therapy?” 2016). 
Gene Editing Overview 
 Gene editing is a technique used to modify DNA within a cell. Engineered 
nucleases are used to make cuts at specific locations in efforts to add, remove, or change 
DNA within the genome (“What Is Genome Editing?” 2017). Engineered nucleases are 
made up of a nuclease that cuts the DNA and a DNA-targeting portion that guides the 
nuclease to the appropriate and specific sequence of DNA that is being targeted. After the 
cut is made the cell naturally repairs the cut. 
 The several types of genome editing include small DNA changes, DNA removal, 
and DNA insertion. These various methods are utilized to create a specific result. Small 
DNA changes occur when an engineered nuclease is utilized to cut DNA and the cell 
repairs the cut. During this process, bases can be lost or added around the site of the cut, 
therefore changing the function of the DNA. DNA removal involves the engineered 
nuclease targeting a section of DNA to remove. After the DNA section is cut, the cell’s 
DNA repair machinery may join the wrong ends of DNA together causing a removal of 
DNA. DNA insertion leverages the DNA repair system to insert a section of DNA. An 
engineered nuclease is utilized to cut the DNA at a specific location. Once the DNA is 
cut, a modified section of DNA is introduced, and the cell’s repair machinery utilizes the 
modified piece of DNA as a template to repair the break (Figure 4). This approach can be 
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used to insert new DNA or to replace existing DNA with a changed version in order to 
correct mutations. 
 
Figure 4 – DNA Insertion through Gene Editing.  An engineered nuclease is 
used to cut DNA at a specific section and new section of DNA is introduced to act 
as a template for the cell’s DNA repair machinery. 
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 There are several types of engineered nucleases. These include ZFNs, TALENs 
and CRISPR/Cas9 (Figure 5). ZFNs and TALENs use proteins to detect and bind to 
specific DNA sequences. This becomes expensive and inefficient as a new nuclease must 
be engineered for each genomic target. CRISPR/Cas9 utilizes RNA sequences to bind to 
target DNA which allows for more simplicity and adaptability. CRISPR/Cas9 is cheaper, 
more efficient, and easier to access because of its use of RNA versus proteins (“Addgene: 
CRISPR Guide” n.d.; “What Is Genome Editing?” 2017; Petersen 2017). 
 
 
Figure 5 – Types of Engineered Nucleases. (A) ZFNs and (B) TALENs utilize 
proteins to detect and bid to target DNA. Meanwhile, (C) CRISPR/Cas9 utilizes 
RNA to locate target DNA sequences (Petersen 2017). 
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 Because CRISPR/Cas9 is a more easily applied method, the remainder of the 
literature review will focus on CRISPR/Cas9 and its applications for gene editing and 
treatment for genetic diseases. 
CRISPR/Cas9 Overview 
 CRISPR/Cas9 is a gene editing tool that is notably more efficient, cheaper, and 
accessible than other methods (Petersen 2017). CRISPR/Cas9 supports gene therapy in its 
ability to remove, add, or alter sections of DNA (“What Is CRISPR-Cas9?” 2016). 
 There are two key molecules that enable CRISPR/Cas9’s gene editing function. 
The first key molecule is the enzyme Cas9. Cas9 acts as ‘molecular scissors’ that can cut 
DNA at a specific location for DNA addition or removal (“What Is CRISPR-Cas9?” 
2016). The second key molecule is guide RNA (gRNA). The gRNA is a piece of RNA 
pre-designed to bind to the specific section of DNA where Cas9 must cut DNA 
(“Addgene: CRISPR Guide” n.d.; “What Is CRISPR-Cas9?” 2016). The gRNA has about 
20 nucleotides with complementary bases to the targeted section of DNA, suggesting 
precise Cas9 cuts in the genome. In order to target different sections of DNA, one must 
only change the gRNA. After the gene is cut in the proper location, various methods can 
be used to change the or repair the gene of interest. 
  CRISPR/Cas9 can be used to create knockout cells as long as two requirements 
are met. A genomic target can be any DNA sequence of approximately 20 nucleotides in 
length as long as the sequence is unique compared to the rest of the genome and the 
target is immediately adjacent to a Protospacer Adjacent Motif (PAM) (Petersen 2017). If 
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the genome target is not unique, unintended edits can occur. Moreover, the PAM 
sequence is critical as it prevents the CRISPR locus from targeting itself and serves as a 
binding signal for Cas9. PAM sequences may vary with Cas proteins.  
 Once a CRISPR/Cas9 system is expressed, the Cas9 and gRNA form a 
ribonucleoprotein complex through electrostatic interactions between the gRNA scaffold 
and the positively charged grooves on the Cas9 protein. With complex formation 
completed, the Cas9 protein changes from an inactive conformation to an active DNA-
binding conformation. Additionally, the gRNA remains free to bind to and interact with 
the target DNA. 
 Once the Cas9-gRNA complex identifies and binds to a DNA target in which the 
gRNA shares sufficient homology, the seed sequence (8-10 bases on the 3’ end of the 
gRNA) will begin to anneal the target DNA. If the seed sequence matches the target 
DNA, the gRNA binds to the target DNA in a 3’ to 5’ direction. Cas9 will then go under 
a second conformational change upon binding the target DNA that positions the nuclease 
domains to cleave opposite strands of target DNA. Cas9 cleavage results in a double-
strand break within the target DNA, approximately three to four nucleotides upstream of 
the PAM sequence (Figure 6). 
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Figure 6 – CRISPR/Cas9 Knockout Formation. Cas9 and gRNA form a 
complex to discover and anneal to the target DNA sequence. Cleavage occurs 
forming a double strand break (“Addgene: CRISPR Guide” n.d.). 
 
 There are two pathways by which the resulting double strand break can be 
prepared. These DNA repair pathways include the non-homologous end joining (NHEJ) 
pathway and the homology directed repair (HDR) pathway (Figure 7).  
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Figure 7 – NHEJ and HDR DNA Repair. The NHEJ DNA repair system is 
highly efficient but imprecise and can lead to insertions or deletions. The HDR 
repair system is not very efficient but can lead to specific changes including the 
complete addition of a new DNA sequence (User:Mariuswalter 2017). 
 
The NHEJ pathway is efficient but error prone as it can often result in small 
insertions or deletions (indels) which subsequently can disrupt gene function (Petersen 
2017). NHEJ double strand break repair is random and can cause various mutations such 
as amino acid deletions, insertions, or frameshift mutations which can all result in 
premature stop codons within the open reading frame of the target gene sequence. The 
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ideal result when using the NHEJ pathway is a loss of function mutation (“Addgene: 
CRISPR Guide” n.d.). 
The HDR pathway is less efficient compared to the NHEJ pathway but has higher 
fidelity. HDR uses a homologous template to conduct the repair of the double strand 
break and can result in specific nucleotide changes (“Addgene: CRISPR Guide” n.d.; 
Petersen 2017). The repair template contains the desired changes and a homologues 
sequence upstream and downstream of the target sequences, or more easily known as left 
and right homology arms. Homology arms vary in length and depend on the size of 
change desired. The repair template must not include a PAM sequence in order to prevent 
alteration of the repair template. The efficiency of HDR is low and is often augmented by 
synchronizing cells so that HDR occurs in the S and G2 phases of the cell cycle 
(“Addgene: CRISPR Guide” n.d.).  
A significant amount of double strand breaks will be repaired by NHEJ versus 
HDR because HDR is far less efficient while Cas9 cleavage is highly efficient. This can 
result in a cell population containing wild type alleles, NHEJ-repaired alleles, and HDR-
edited alleles. Desired edits must be confirmed through further, detailed experimentation. 
Potential Applications for CRISPR/Cas9 
There are several potential applications of CRISPR/Cas9, especially in the current 
era. The CRISPR/Cas9 system is a widely flexible tool as Cas enzymes bind target DNA 
independent of the system’s ability to cleave target DNA (“Addgene: CRISPR Guide” 
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n.d.). The system’s potential to efficiently and precisely target, edit, regulate and mark a 
genomic locus has various uses. 
CRISPR/Cas9 can be used for precise genetic manipulation in a wide array of 
organisms (Wright, Nuñez, and Doudna 2016) . The application of the CRISPR/Cas9 
system can include the generation of engineered animal models that can actively benefit 
the knowledge of understanding. Furthermore, CRISPR/Cas9 can be used to treat the 
human diseases associated with the genetic disorders. The main goal of this system is to 
correct the mutations at various precise locations in the human genome to treat the actual 
course of genetic causes of a disease, which usually include various disorders and 
diseases that largely affect the public. 
PUBLISHED STUDIES 
The studies cited in this thesis were primarily discovered by searching for articles 
using the PubMed database.  
LITERATURE REVIEW 
  There are various applications for gene editing with current diseases. Currently, 
observed applications include treatment for retinal diseases, Huntington’s disease, and 
Alzheimer’s disease. This thesis focuses mainly on the potential applications of 
CRISPR/Cas9 as it has been noted as an efficient and cheaper method, giving it more 
potential for therapeutic use. 
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Application of CRISPR/Cas9 for the treatment of Retinal Diseases 
CRISPR/Cas9 is a current system of genome editing which has been 
revolutionized by molecular biology and offers a simple, relatively inexpensive method 
of inducing new DNA edits. One of the applications for utilizing the CRISPR/Cas9 
system includes the treatment of retinal diseases. 
Gene therapy has the potential of treating retinal diseases because it provides 
targeted diseases with the appropriate need for altering transcriptionally regulated 
pathogenic genes. Studies provided in vivo showcase the benefits associated with therapy 
among a variety of conditions. The evolving CRISPR/Cas9 based genome editing system 
is a technology that has rapidly changed the life sciences. Both nonviral and viral vector 
has been mediated and developed for transient and persistent expression of CRISPR 
components that are found in retinal cells.   
There are various applications for CRISPR/Cas9 treatment when considering 
precise modification and edit, which mostly relies on HDR double strand break repair 
systems. Developing CRISPR treatment of retinal diseases also focuses on gene knock 
out and deletion, which utilizes the highly efficient NHEJ pathway of repair. There are 
many benefits associated with gene therapy as showcased by different models including 
those of rodent models which help in the understanding of retinal diseases. In vivo 
application, while using CRISPR has the capacity of facilitating the gene functions 
around the retina. However, off target changes and inadvertent immune responses remain 
an issue for the use of CRISPR/Cas9 systems for gene editing. These underlying issues 
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prevent the development of CRISPR/Cas9 genome editing systems for use and 
availability for clinical applications.  
Genome editing refers to a current technique in the field of medicine which 
attempts to modify cell organisms. The process introduces engineered nuclease which 
generates double-strand break at specified location of the genome that follows 
endogenous repair through an active process of NHEJ repair. The retina is a light-
sensitive layer of tissue lining at the back of the eye that sends visual messages through 
an optic nerve which sends signals to the brain (W. Yu and Wu 2018). There exist a 
variety of retinal disorders that cause visual impairment and irreversible blindness which 
affects many people around the globe. Inherited retinal disorders are caused by mutation. 
These disorders are prime targets for gene editing intervention. Gene editing can 
modulate the pathways associated with diseases, especially issues associated with 
macular degeneration, glaucoma, and diabetic retinopathy.   
Precise gene therapy is preferable to gene replacement or augmentation because 
of its permanent effect. However, gene editing was rarely used in retinal diseases prior to 
the introduction of the CRISPR/Cas9 system. The delivery of ZFNs and TALENs have 
too large of coding sequences and were too complex to design.  
Viral and non-viral modalities recently offer profound methods of delivering 
CRISPR components to the retina. Electroporation components have been previously 
used, and effective genome editing was transferred successfully to the retina areas (S. 
Wang et al. 2014). Transfected cells in the area include bipolar cells, amacrine cells, and 
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Muller glial cells (Dhande and Crair 2011). With efficient transfection, however, 
professionals can achieve electroporation approach on newborn rodents to induce retinal 
cells while in the mitotic phase. The method is not appropriate for therapeutic purpose 
because usually, the retinal symptoms are present when a retinal cell has entered the 
postmitotic phase. 
Adeno-associated viral (AAV) vectors have been the most successful in the in 
vivo delivery to the retina. AAV-mediated CRISPR/Cas9 delivery was first applied to 
mouse brains (Swiech et al. 2015). Generally, a dual vector system is used with one 
vector carrying the Cas9 enzyme and the other carrying the gRNA as seen in the 
successful knockout of the Yellow Fluorescent Protein (YFP) gene in mouse retinal cells 
with AAV type 2 (AAV2)-mediated CRISPR delivery (Hung et al. 2016). More AAV 
variant allow for sager and more efficient CRISPR delivery to the retina (W. Yu and Wu 
2018). However, as short coding sequences of the newly discovered Cas9 nucleases from 
Staphylococcus aureus (SaCas9) could allow for the delivery of Cas9 and gRNA in a 
single vector (Ran et al. 2015). Furthermore, there exist concerns with the cytotoxicity of 
AAV-mediated persistent expression of CRISPR (W. Yu and Wu 2018). These concerns 
can be mediated by the transient expression of CRISPR/Cas9 with the use of cationic-
lipid mediated delivery (Kim et al. 2017). 
 In theory, HDR repair methods are ideal as they can provide precise gene edits. 
However, as many retinal cells are of a postmitotic nature, HDR methods for DNA repair 
are too inefficient for a significant effect (W. Yu and Wu 2018). Thus, NHEJ gene repair 
is the optimal approach for retinal diseases. Therefore, distinction between the mutant 
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and wild type alleles is critical for success. In one study, use of the CRISPR/Cas9 system 
resulted in prevention of retinal degradations and improved visual function, however 
there we issues with distinction between the wild type and mutant alleles  (Bakondi et al. 
2016). More promising results were derived from a study focusing on the P23H mutant 
allele. A Cas9 variant paired with a gRNA complementary to the P23H mutant which 
also maintained one mismatch with the wild type allele was effective in indel formation 
only in the mutant allele (Giannelli et al. 2018). 
Other successful results have occurred with different approaches. After using 
CRISPR to disrupt the neural retina leucine zipper (Nrl) gene, which encodes a 
transcription factor that determines rod cell fate, Nrl expression was markedly reduced in 
rods, resulting in a gain of certain cone features and partial loss of rod function (W. Yu et 
al. 2017). Currently, the inhibition of neovascularization using anti-vascular endothelial 
growth factor (VEGF) agents is widely used for diabetic retinopathy but requires 
repetitive administration. CRISPR has been successfully utilized to disrupt the VEGFa 
gene through NHEJ methods (Kim et al. 2017). 
Application of CRISPR/Cas9 in the Treatment of Huntington’s Disease 
The CRISPR/Cas9 shows promise of treating Huntington’s disease (HD). HD is a 
genetic disorder associated with the expansion of CAG repeats in exon 1 in the mHTT 
gene, which can encode mutant Huntington mHTT (Nopoulos 2016). There exists a large 
protein mass which consists of large polyglutamine repeats which occurs in the N-
terminal domain of mHTT that mostly shows a toxic gain of function. There is a common 
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potential strategy that is used to treat HD, which can use CRISPR/Cas9 to suppress the 
mHTT selectively. The approach was borrowed from another study that demonstrated the 
actual application of RNA interface, which was meant to improve both the 
neuropathological and motor defects in an HD mouse approach (Carbery et al. 2010). The 
CRISPR/Cas9 form of gene editing has showcased its ability of how it can successfully 
apply in HD (Rohn et al. 2018). CRISPR/Cas9 has previously been used to selectively 
suppress the entire mHTT gene and HTT in an (in vivo) mouse model of the non-allele 
specific approach of HD (Yang et al. 2017). The process was achieved through an active 
process that showcased the depletion of normal HTT in the adult mouse brain because it 
does not affect the healthy growth and survival or even the neuronal viability (G. Wang et 
al. 2016). This showed that the removal of N-terminal HTT containing the polyQ domain, 
regardless of its allele, could be a potential therapeutic strategy to treat HD. 
One of the main challenges of using the CRISPR/Cas9 in the HD model is to 
target the gene editing system in the appropriate area of the brain. The approach is 
achieved with the incorporation of AAV methods and also via the process of injecting the 
viral vectors that carry CRISPR/Cas9 into the striatum region of the brain of a nine 
month old mouse that has HD (Yang et al. 2017). AAV-HTT-gRNA transduced most of 
cortex’s striatum located in the brain region after the active process of injecting AVV-
CMV-Cas9 and AAV- HHT-gRNA in one side of the striatum occurring in the nine-
month-old homozygous HD14-KI mice. The results led to a sudden decrease in the 
aggregate mHTT in the striatum several weeks later (Figure 10). As such, the study 
results demonstrated a level of improvement of motor performance, which included the 
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grip and balance in treated mice. Yang et al also discovered some potential off-target 
gene effects that appear to be specific to gene editing with HTT and mHTT.  
 
Figure 8 – CRISPR/Cas9 Applications for Huntington’s Disease. 
CRISPR/Cas9 gene editing reduces the pathology of Huntington’s disease in a 
mouse model (Rohn et al. 2018). (A)Immunofluorescence showcases the 
transduction of AAV-HTT-gRNA in various parts of the cortex and also the 
striatum. (B) Subsequently there is a reduction of HTT aggregates with the area 
treated with Cas9 and gRNA compared with the control treated with gRNA only. 
The red dashed line indicates the area where there is significant reduction in 
mHTT aggregates. 
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Furthermore, there are several extensions that attempt to use the CRISPR/Cas9 
gene editing system along with a nickase version of Cas9 which also appears to be safer 
and more specific (Dabrowska et al. 2018). One of the advantages of this version is that 
the Cas9 cuts only one DNA strand instead of the two. As such, it increases the precision 
in which can either be used to edit the sequence of the DNA. Dabrowska et al 
demonstrated that the CAG repeat within the HTT gene can be removed with proper use 
of the Cas9 nickase strategy. The process resulted in markedly reduced huntingtin 
synthesis in HD patient-derived fibroblasts and reduced pathology (Dabrowska et al. 
2018). 
Overall, the above findings suggests that the CRISPR/Cas9 system has the ability 
to efficiently correct the mutant protein expressed in the specific part of the brain thus 
opening up the possibility of new treatment management strategy not only for the HD but 
also other neurodegenerative diseases that emanate from the stem of mutant genes. 
Another good example of where CRISPR/Cas9 has great potential in neurogenerative 
disorders is Alzheimer’s disease.  
Therapeutic application of CRISPR/Cas9 in treatment of Alzheimer’s Disease 
Over the past three decades, there has been a considerable amount of knowledge 
surrounding Alzheimer’s disease (AD). There has been progress obtaining effective 
disease therapies, although there are a lot of underlying questions.  There have been 
numerous clinical trials that target the production, toxicity, and aggregation of beta-
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amyloid, although researchers have failed to attain the target efficacy standards. As such, 
there is an underlying question as to whether the beta-amyloid hypothesis is appropriate 
because it suggests that there is a need to explore more appropriate treatment strategies. 
With the emergence of the CRISPR/Cas9 system, gene editing has been presented as a 
cost-effective solution. CRISPR gene editing can be used as a direct approach to treat or 
help to establish better animal models that mimic neurodegenerative diseases among 
humans. Moreover, CRISPR/Cas9 offers an innovative, tailored solution for AD, which 
has increased the interest utilizing the strategy for further studies of AD and potential 
treatment modalities (Rohn et al. 2018). 
Alzheimer’s disease commonly referred to as (AD), is termed as a fatal 
neurodegenerative disorder that commonly affects the adult population and is one of the 
contributors to dementia (Jack et al. 2018). Currently, AD has affected over five million 
Americans, and the number is predicted to triple by the year 2050 (“Facts and Figures” 
n.d.).  Currently, it is one of the main causes of death among the Americans, although it 
comes after cancer and heart disease. It is predicted that over 700,000 Americans who 
age 65 years and above will have the disease by the time they die. Furthermore, the cost 
of treating AD disease is considered substantial. 
Patients with the disorder present progressive memory loss and cognitive ability 
reduction, however, can take up to several years to display symptoms. Furthermore, 
patients with the disease are prone to experiencing language difficulties and issues with 
other learned skills. As such, AD interferes with memory, thinking, and overall behavior, 
which can ultimately affect the ability of a person to work and maintain a relatively 
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healthy quality of life. Moreover, the condition is inexorably progressive, and usually 
becomes fatal between 5 - 10 years.  
The neuropathological footprints of AD feature similar senile plaques to beta-
amyloid, hyperphosphorylated tau, and intracellular lesions which can cause 
neurofibrillary tangles (Van Dam et al. 2016). AD can present with synapses loss, 
although AD most significantly correlates with cognitive impairment (Nelson et al. 
2012). According to the recent AD studies, brains can document the early accumulation 
of beta-amyloid when viewed in the PET scans from an early age even before the 
symptoms are presented (Vlassenko, Benzinger, and Morris 2012). This suggests that 
there is a potential therapeutic window where treatment should be initiated. Furthermore, 
beta-amyloid when in toxic oligomers is thought as a potential cause of synapse loss, 
neurodegeneration, and eventually dementia.  
The beta-amyloid hypothesis that was critical in understanding AD and further 
development of treatment of AD (Hardy and Allsop 1991). However in a recent study, 
the beta amyloid hypothesis has seemingly been replaced by a more holistic approach for 
identifying AD and associated risk factors (Osorio et al. 2019). With more reports failing 
in the current approaches to understanding current diseases, there is a need to focus on 
various treatment options, which include the gene editing systems (Rohn et al. 2018).  
Currently, there exist three commonly used gene editing tools which researchers 
can use to address AD. They include ZFNs, TALENs, and CRISPR/Cas9. All the gene 
editing tools have various advantages and bottlenecks. For instance, the CRISPR/Cas9 
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technique is considered to be cheaper and faster, efficient, and accurate than any other 
form of methods of genome editing. Furthermore, the success of these techniques is 
demonstrated in various diseases. 
The majority of cases of AD are sporadic because the trigger is not well known. 
The use of CRISPR/Cas9 may not seem like the best approach to treat the disorder. It is 
supported by the fact that only a small number of cases can be attributed to APP 
mutations found in protein and genes products that are involved in the actual process of 
APP transformation to form a beta-amyloid (Bettens, Sleegers, and Van Broeckhoven 
2013). One thing that is certain is that these mutations make up only a small percentage 
of AD cases which lead to more enhanced production and formation of a beta-amyloid 
peptide. Besides, there are other forms of mutations that contribute to the early onset of 
AD which includes the presenilin 1 (PSEN1) and presenilin 2 (PSEN2) (Levy-Lahad et 
al. 1995; Schellenberg et al. 1992). 
The net mutation effects of both PSEN1 and PSEN2 genes is achieved through 
the production of a beta-amyloid (1-42), which mainly occurs because of shifting the 
APP cleavage site (Vetrivel et al. 2006). The majority of these cases are mainly 
manifested before the active age of 60, and therefore they are classified as an early form 
of early onset, indicating that there is potential for the implementation of a CRISPR/Cas9 
strategy. 
A recent study examined CRISPR/Cas9 to analyze the potential of correcting a 
PSEN2 mutation in iPSC-derived neurons via the incorporation of the use of gene editing 
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system (Ortiz-Virumbrales et al. 2017). CRISPR/Cas9 was initially used to correct 
presenilin (PSEN2) autosomal dominant mutations in iPSC forms delivered from the 
neurons (Ortiz-Virumbrales et al. 2017).  In the same study, the researcher generated 
basal forebrain cholinergic iPSC neurons from individual people carrying PSEN2N1411 
mutation and was able to use CRISPR/Cas9 to correct the N141I mutation. This led to a 
normalization of the Aβ 42/40 ratio and a reversal of electrophysiological deficits (Figure 
9) (Ortiz-Virumbrales et al. 2017). The study is also supported by another successfully 
CRISPR/ Cas9 correlate with correcting appropriate AD mutations in the PSEN gene 
amongst the patient-delivered iPSCs (Pires et al. 2016) 
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Figure 9 – Alzheimer’s Disease Correction through CRISPR/Cas9. 
CRISPR/Cas9 has the potential to correct AD (Rohn et al. 2018). (A) Sanger 
sequencing results display correction in the N141I mutation (left) and a 
normalization of the Aβ 42/40 ratio (right). (B) CRISPR/Cas9 gene editing action 
of PSEN2 mutation diminishes electrophysiological deficits and the 
electrophysiological number of spike and spike height to wild type levels. 
 
In a recent study, CRISPR/Cas9 AAV vectors transferred to the hippocampus 
were used to knock out the Swedish APP mutation in patient-derived fibroblasts leading 
to a 60% reduction in the selection of beta-amyloid (György et al. 2018). The Swedish 
mutation is thus the only known to secretase which is actually in the form of double 
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mutate that result from substituting the main two amino acids, that is the methionine and 
lysine to leucine and asparagine (Mullan et al. 1992). However, it must be noted that 
direct injection of CRISPR/Cas9 into the hippocampus led to a low percentage of 
transgenes changed in the injected area (György et al. 2018). This low level of impact 
could be attributed to an insufficient level of CRISPR/Cas9, however, more studies of 
targeted approaches in the hippocampus must be completed to comprehend low editing 
efficiency in vivo. 
The aforementioned studies examine CRISPR/Cas9 viability in early onset AD, 
but sporadic AD represents the vast majority of cases in the United States (Rohn et al. 
2018). The current findings in cultured neurons, cell lines found in human iPSC neurons 
as well as the brain of the mouse have showcased that the strategy works via the process 
of limiting the physical association of APP with BACE-1 and attenuating in the 
production of beta-amyloid production (Das et al. 2013). 
Other major risks associated with the development of the late-onset AD is 
apolipoprotein E4 (APOE4) allele (Eisenstein 2011). Human apoE is polymorphic with 
three main forms which include apoE2, apoE3, and apoE4. Each of these isoforms differ 
by the substitution of a single amino acids which involves cysteine-arginine replacements 
at positions 112 and 158 (Weisgraber, Rall, and Mahley 1981). The E2 allele is a rare 
form because even with a single copy, there is a 40% reduction in the risk of AD 
development. 
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On the other hand, the APOE3 allele is the most common and does not seem to 
influence the risk although APOE4 represents approximately 10-15 % of the population 
thus increasing the risk of AD while lowering the age on the onset (Farrer et al. 1997). 
Availing one copy of E4 can increase the risk from 2 to 3 times while two copies of E4 
can intensify because it increases the risk by 10-15 times (Eisenstein 2011). Finally, 
because many adverse effects of APOE4 are commonly associated with beta-amyloid, a 
recent study has concluded that apoE4 can promote pathology like tau phosphorylation 
on iPSC derived neurons (C. Wang et al. 2018). Wang et al showcased that the process of 
converting apoE4 to Apo E3 via ZFN gene editing actively prevented the pathology 
associated with apoE4 according to the mode. As such, one potential use of CRISPR/ 
Cas9 system is to convert APOE4 allele to either APOE3 or E2 which takes an 
integrative approach of domain interaction that is mediated by salt that bridge between 
Glutamine-255 and Arginine-61 (Dong and Weisgraber 1996). These suggest that the use 
of CRISPR/Cas9 to alter the two components of amino acids may be termed effective 
when it comes to neutralizing the risk associated with harboring E4 allele. 
CRISPR/Cas9’s efficiency and ability to virtually target any gene makes it an 
appropriate strategy for various mutations and risk factors associated with earl-onset and 
late-onset AD. However, off-target effects and specific cell delivery continues to present 
as a challenge. 
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DISCUSSION 
Gene therapy and gene editing are just a small piece of the future of precision 
medicine that moves away from the average patient and moves towards specific 
treatments for individual patients, sometimes referred to as personalized medicine. Cell 
therapies and somatic gene therapy are widely viewed as morally acceptable (Gyngell, 
Douglas, and Savulescu 2017). For instance, bone marrow transplant takes place when 
cells that differ in genetic composition are introduced to different patients. Besides, this 
has happened for many decades, whereas gene therapy is only recently being used to treat 
patients with severe medical disorders and deficiencies.  
While considering other issues of efficacy, safety, and informed consent and such, 
there lacks a valid concern about the issue of gene therapy and somatic cell changes 
among different people who appreciate modern medicine. Genome editing plays a critical 
role in increasing somatic gene therapy to prevent and treat some diseases. Considering 
the vast advances in technology, the probability that gene editing can be used for more 
gene therapy increases. However, there is an underlying question as to whether such 
enhancement should be prohibited (Cribbs and Perera 2017). Furthermore, there exists 
another issue as to whether there are appropriate differences that depend on whether the 
enhancement is heritable or somatic. 
This thesis explores possible applications of genome editing in an attempt to 
achieve an understanding as to whether enhancement can be problematic. Enhancement 
can be seen as precarious because it implies different changes that assert improvement of 
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existing conditions. As such, enhancement from cosmetic changes like the color of hair 
and other physical interventions can bring about dangers to human beings when 
considering ethics.  
Enhancement is easily understood by referring to changes that alter the normal 
way of human behavior. As such, there is an underlying question of what is meant by 
normal, especially when enquiring whether it is average or whether it complies with what 
nature prescribes. Considering the wide view of capabilities displayed by humans at any 
one particular trait, there is the little basis of deeming any normal conditions with a 
conducive environment which are consistent with various activities that people engage in 
around the world. There are several issues that are involved in genome editing to 
facilitate enhancement.   
To understand the concept of enhancement, it is critical to understand various 
terminologies that relate to genome editing and human gene therapy. Consequently, some 
diseases are associated with variants of DNA. Moreover, there are common terms that are 
used to describe mutation which has taken a negative connotation. There is a big 
distinction between normal and mutant causing genes, and the latter is considered 
harmful (National Academies of Sciences et al. 2017). Besides, the word “normal” is 
commonly used in phenotype or other individual traits that come as a result of the 
interaction of genotype in the environment. As such, “normal” is denoted as the spectrum 
rather than the ideal state. Furthermore, the word “natural” similarly takes a positive 
connotation reflecting a common approach that suggests that nature has the capacity of 
producing healthier things as considered to the artificial things despite the considerable 
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amount of evidence that demonstrates that natural things are either healthier or 
intrinsically dangerous. While viewing the present context, it seems that genetic variants 
that exist naturally can either support or cause disease. The human population, on the 
other hand, contains multiple variants which consist of most genes and as such there is no 
single “normal” genome sequence among the humans but instead there exist multiple 
variant consequences of the human genome. This wide variety is part of the reason why 
medicine aims to move away from the average patient and towards tailored, individual 
treatments. Genome results are advantageous, while others are detrimental. 
Some of the effects depend on various conditions, which include the action of a 
person holding one copy of heterozygosity and double copies of homozygosity of the 
variant. Other factors include whether the possessed gene is the sex chromosome, which 
is linked to hemizygous and is found on the X chromosome. Another underlying factor is 
the environment in which a person is located. A good example is sickle cell anemia 
(Luzzatto 2012). Hemoglobin is a type of protein that induces oxygen in the red blood 
cell. The common variant which is widely spread and encodes a functional protein 
whereas the sickle cell variant is used to aggregate the protein and distort the red blood 
cells to form a sickle shape if the copies of the gene are the variant.  
The effect of the homozygous state is attributed to the sickle cell disease. 
However, a person who is heterozygous for this variant can resist some disease-causing 
microorganism such as malaria and as such, the sickle cell variant is beneficial, especially 
in places where the prevalence rate of malaria is high. However, the disadvantage of 
sickle cell disease at various population levels has been balanced against the population 
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level is advantageous when it comes to the resistance of malaria. As such, the 
environment plays a critical role in determining the benefit of the natural variant.  
The term variant is actively used to refer to the gene variant. Many variants 
appear in natural form and changing the variant of the gene that is associated with the 
disease. For instance, the sickle-cell variant affects the hemoglobin to a variant that is 
prevalent in the natural population. However, in this case it is not a disease-causing 
variant and thus is viewed as a way of prevention. However, it is essential to consider that 
the concept of changing a gene to a variant form may not be true as a variant form could 
exist and just be rare in the gene pool. The human gene pool has some property which 
can be viewed as a form of enhancement because it is predicted to be advantageous. Gene 
editing and enhancement is considered radical because of its ability to replace a certain 
disease and drastically change the genome. However, variants exist and are changed via 
natural selection and this is not considered radical. 
It is not yet clear as to whether the activity of genome editing for enhancement 
follows a pattern of disruptive application such as the new forms of technology that are 
resistant and persist over time. However, there are new concerns as to whether problems 
will arise because of continuous technology progression and new applications and 
technology constant to emerge (Shwartz 2018). 
Somatic versus Germline Gene Editing 
Although somatic gene editing affects some cells in the patient undergoing 
treatment, it is clear that germline editing has the capacity of affecting all the cells of the 
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organism including the eggs and sperm and as such can be passed to the future 
generations. Due to the concern of passing on gene editing changes and the risk of off 
target gene edits, it becomes difficult to predict the possible future outcome of gene edits.  
Somatic gene therapies take an integrative approach of modifying patient DNA in 
an attempt to treat and cure all forms of disorders associated with the genetic mutation.  
For example, a clinical trial will take place that will take the blood stem cells from the 
suffering patient and use the CRISPR techniques to adjust the error of genetic mutation 
by causing them to produce new defective blood cells (Shwartz 2018). The cells are 
infused back into the patient, where they later produce healthy hemoglobin. The medical 
procedure changes the patient’s blood cells, but other cells, including the sperm and eggs 
cell, are left unaffected.  
Germline human genome is a form of editing that alters the genome of the human 
embryo during the early stage of life (Gyngell, Douglas, and Savulescu 2017). The 
procedure has the capacity of affecting a single cell, meaning that it does not only impact 
the one person but may be passed from one generation to another. Therefore, there exist 
ethical issues surrounding the substantial restriction on the usage of germline human 
genome form of editing. 
Facilitating the process of germline editing in a dish has the capacity of helping 
researchers to come up with the best approach of the benefits of health as well as 
understanding how it can reduce the risks. The process includes the active process of 
targeting the wrong gene. This sort of testing shows off target effects and subsequent 
	38 
adverse impacts from on target edits to ensure that the process of gene editing does not 
fix the problem and create another one. Besides, gene editing in mosaicism occurs when 
only several copies of the gene are altered, and due to many reasons, the scientific 
community approaches the process of germline editing with a lot of precaution. There are 
some regulations but there is still debate on the matter with several countries allowing 
edits on human embryos (Friedman n.d.). 
Contrary to the issue, some scientists suggest that if the benefits of genome 
editing outweigh the risks and if the danger can easily be avoided, science should 
consider moving with the germline genome editing to improve health of the overall 
population. However, these sorts of decisions have widespread impacts and can also lead 
to unintended consequences. Society must determine strict guidelines so that people who 
do the work can proceed responsibly with the appropriate quality control and oversight. 
“Designer” Babies 
Medicine is at a turning point for the human race considering the profound 
changes of technologies including gene, RNA, and cell therapies which enable scientists 
and concerned researchers to approach disease research and management in many ways, 
including root causes. The change has become swift, considering it is driven by 
innovative changes such as CRISPR/Cas9 gene editing which has made it possible to 
correct underlying errors in the DNA at a lower cost and lasting impact. However, this 
progress in the medical field poses potential societal, ethical, and safety issues.   
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   A prevalent concern around using CRISPR/Cas9 or other gene therapies is the 
use of these techniques to edit embryos to create “designer babies” with traits chosen by 
the experimenter (Shwartz 2018). During the second international summit on the issue of 
human genome editing updates in 2018, a Chinese researcher named He Jiankui claimed 
that he had edited the genes of two human embryos that had been brought to the term 
(Rana 2019). There was an immediate outcry from different scientists from different parts 
of the world. Furthermore, the Chinese scientist was subjected to social pressure, 
including the removal of his affiliation because of disregarding ethical norms as well as 
the safety of the patients. He’s goal was to protect babies from HIV by introducing a 
mutation to the CCFR5 gene that improves HIV resistance, however it is uncertain if the 
edits could have off target effects and impact the patients later in life (Cyranoski 2019). 
More recently, a Russian scientist named Denis Rebrikov has announced that he plans to 
similarly produce gene-edited babies to improve HIV resistance with a similar edit. 
(Cyranoski 2019). Rebrikov believes that the benefit of gene therapy outweighs the risks 
as he plans to implant gene edited embryos in women who are infected with HIV but do 
not respond well to anti-HIV drugs. With Rebrikov’s announcement prior to action, the 
scientific community has an opportunity to discuss the concerns and risks with germline 
gene editing rather than just condemning him (“Act Now on CRISPR Babies” 2019). 
Ample communication and debate could discourage other germline gene edit attempts, 
especially those that are not publicly known.  
 Germline gene edit attempts for increased resistance are only part of the problem. 
In theory, CRISPR/Cas9 gene editing strategies could be used to produce “designer 
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babies,” specifically to change phenotypes and other superficial factors. Although this 
risk remains science fiction, the possibility remains if the correct genes were targeted. In 
order to reduce the chance of rogue scientists attempting phenotype changes through gene 
edits, relevant stakeholders must communicate and enact regulation. 
Bioethics 
Apart from the many risks associated with safety risks, the human genome editing 
poses hefty ethical questions. Families have watched their children suffer from unending 
misery and suffering as a result of genetic diseases. While the technology offers the hope 
of editing the mutations in the gene pool, many people who live in poverty are yet 
unprivileged because of the cost associated with a genetic disorder and actual treatment.  
As such, there is an underlying issue while attempting to understand the extent to which 
we should draw the line to enhance and treat actual disease as well as the general 
availability of the treatment (Smith 2018). As regulations are further developed, public 
opinion and well-being must be heavily considered.  
The underlying question is not as easy as it seems but with the evolution progress 
of random mutations with CRISPR, has changed things because they can be done 
artificially.  Random mutations have caused many problems, while people are born with 
serious defects. Additionally, humans have been manipulating the environment in many 
aspects that expose human to many chemicals that can cause unknown changes to our 
genome. If a human is to talk about inducing into board precise interventions to cure 
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diseases, there is a viable need to discuss access. However, access is generally affected 
by cost.     
Financial and Business Considerations  
It is by no means that the actual process of gene editing incorporates the use of 
technology that is potentially transformative. This is an ultimate goal in the procedure. If 
one can actively correct and delete the genes that cause the problems of mutation and 
aberrant genes, then it can be considered as a precise method. Besides, it would appear to 
transformative for the people who have diseases that are caused by a single gene 
mutation. There is much potential in developing effective methods of using gene editing 
to treat people with serious diseases that have no known cures, and this has much 
potential to relieve suffering. With this in consideration, it becomes difficult to determine 
the widespread resistance to actively applying gene editing techniques for clinical use. 
Apart from the debate from widespread usage of gene editing therapy, there are several 
issues that arise with financial considerations and the commercialization of gene editing.  
The potential to cure a disease is largely driving the commercial aspect of gene 
therapy, and subsequently further refining therapeutic techniques. A considerable amount 
of companies that are opting to go for venture funding among various unusual gene 
therapies are going after difficult medical conditions because no other methods are 
working, and thus venture capitalists are supporting gene therapy research and 
development (Glatter 2018). This push to discover gene therapies is also driving other 
biotechnology advancements. 
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In one economic model it was determined that private sector investments aim to 
develop gene therapy for monogenic diseases are likely to be socially suboptimal 
(Danzon and Towse 2002). Short-term administration regimens tend to yield long term 
therapeutic benefits that have a high probability of meeting payer resistance to one-off 
cost because of constraints associated with big budgets, competitive systems, and various 
concerns that suggest that savings would accrue to future insurers besides, attracting 
high-cost patients (Danzon and Towse 2002).  
Apart from these economic models, there are concerns that health insurance 
companies are unprepared for a wave of gene editing therapies. Changes to payment 
models will occur slowly and not move rapidly enough to keep up with the introduction 
of various gene editing therapies (Elverum and Whitman 2019). Gene editing therapies 
present system-wide challenges in reimbursement, especially considering their high cost. 
The cost for various gene editing therapies has been estimated to range from $373,000 to 
$1 million (Mullin 2017). However, considering costs of other standard treatments, some 
argue that genetic editing therapies may be comparable in cost (Orkin and Reilly 2016). 
As health insurance companies consider systematic models for value-based 
payment, concepts and payment plans for gene editing therapies must be considered. 
Despite the potential cost, preventing access to genetic therapies solely for cost is 
unethical moves away from current industry movements to tailored healthcare solutions 
that have lasting, efficient impacts. 
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Collective Considerations 
The current research on human subjects deals with somatic gene therapy. To 
showcase, a considerable amount of somatic therapy requires repeated applications which 
appear to be much more ordinary than pharmacological treatments. Initially, gene therapy 
was mainly viewed as a procedure meant to correct recessive monogenic defects by 
bringing a healthy copy of the deficient gene in other relevant cells. Somatic gene therapy 
has the potential to bring a therapeutic gene product at the appropriate place of the body. 
The field has increased from gene correction model to gene editing as another drug 
model. The evolution of understanding gene therapy underscores the reasons as to why 
ethical considerations for somatic gene therapy are different from well-known ethical 
principles that apply in various new experimental therapies. 
The current research surrounding the issue of gene therapy focuses more to 
enhance basic human individuals by targeting the therapy of body cells such as blood 
cells and bone marrow. This kind of gene therapy cannot be passed from one generation 
to another. Gene therapy can target sperm and egg cells. However, the process of 
germline gene therapy can allow the gene inserted to be passed from one generation to 
another. Germline gene edits maintain public concern because of the risk of harmful and 
lasting effects. 
Germline gene therapy is a controversial topic. The therapy can spare future 
generations of families that are prone to a genetic disorder, although it might affect the 
development of the fetus, and this has long term side effects that are yet to be known.  
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Besides, people who are affected by germline gene therapy cannot choose whether to 
have the therapy because they are young infants that are yet to be born. 
The biology of gene therapy is complex because there are various techniques that 
are required to be developed. Besides, diseases need to be understood fully before 
appropriately incorporating gene therapy (Naldini 2015). In addition to this, gene therapy 
involves the process of managing the genetic body setup. Furthermore, it raises a lot of 
ethical concerns. Scientific and ethical discussions about gene therapy were initiated 
many years back, and during early 1990, the human gene therapy was initiated (McCain 
2005). The clinic was considered successful because initially, it was able to improve the 
wellbeing and individual health among patients that were treated during the initial trials. 
However, the success of gene therapy was tentative because many patients had adopted 
the use of traditional medical therapy. As such, it is quite difficult to determine the 
appropriate effectiveness of gene therapy, which is distinct from the efficacy of more 
forms of traditional therapy.  
To measure the success of gene therapy treatment is one of the main challenges of 
gene therapy. Such research is full of ethical and practical challenges. When it comes to 
the drugs of clinical trials, the purpose of human gene therapy in clinical trials is to 
determine the effectiveness of the therapy. To answer the underlying issue, it is important 
to determine the type of dose that is effective and how the therapy should be administered 
to understand how the therapy works. Research on various diseases are based on the 
severity of the disorder because of the more severe the confusion, then the more likely 
health care setup is then different in animal models. There is another ethical issue 
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surrounding the traits and disorders that warrant gene therapy. Consequently, the 
distinction between gene therapy for disease genes and gene therapy to enhance desired 
traits of height and skin color is not clearly stated. Few people will argue that diseases 
that cause suffering, potentially, disability and potential death are good candidates for 
gene therapy.  
However, there is an integral line between diseases and the common traits among 
healthy individuals. Gene therapy that is used for socially unacceptable traits or actual 
enhancement for desirable outcomes may improve the quality of individual life; some 
ethicists fear that availability of gene therapy for trait enhancement can negatively affect 
the socially acceptable traits that are considered normal and as such, they promote 
increased discrimination toward those who have the undesirable trait. Many functional 
genes have continued to be discovered, and as such, it may become increasingly difficult 
to define the gene traits that are considered to be diseases versus the one that should be 
classified as mental, physical, or psychological traits.  
Currently, a form of acceptable gene therapy incorporates the use of somatic cell 
therapies via the incorporation of the use of genes that cause diseases. Contrary to this, 
many ethicists fear that feasibility of germ line gene therapy will improve as more genes 
that cause different traits are discovered. This means that there could be a slippery slope 
that affects the future of practice in gene therapy. As such, it is feared that acceptance of 
germ line gene edits in a form of gene therapy could accommodate and lead to 
acceptance of gene therapy in the active process of genetic enhancement. The public 
debate on the issues of germline gene therapy and trait enhancement is a science that 
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continues to advance in the current gene therapy research. Majority participants in the 
public debate have come from various fields of biology, government, law, and medicine, 
and as such, different researches have differed in addressing the ethical issues 
surrounding gene therapy.  
Different researchers have increased emphasis on both the principle of public 
good and solidarity. The genetics showcase that some diseases are yet to be addressed 
with CRISPR/Cas9. There is of lack of new ethical issues when compared with gene 
therapy and genetic engineering, according to both general and other findings. Several 
other controversies include eugenics, patentability, and unrealistic expectations by both 
the public and professionals.  
The genomic solidarity and priority principle on public good should help provide 
clarity to CRISPR debates (Mulvihill et al. 2017). Experimentation with gene editing 
techniques on germ line cells should be limited because of the knowledge gaps on germ 
cell biology long term risks on future generations. Genetic engineering is a widely 
available tool that is used to alter and correct DNA. Furthermore, it has enormous 
scientific potential following the major biotechnology discovery of the 21st century, 
which have evoked some ethical implications along with legal, financial, and reputation 
consequence.   
Many ethical issues associated with gene editing appear as same as the ones that 
are raised by genetic engineering during the past two decades. However, gene editing is 
not new but is quite different when CRISPR/Cas9 are inducted into the board. 
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CRISPR/Cas9 reduces the overall time required to facilitate various experiments that 
usually took years. 
The shift towards leveraging gene editing therapies for clinical use is inevitable. 
The promise of treatment of diseases at the genetic level is revolutionary and can benefit 
many. However, the correct decisions must be made in the direction of gene editing 
therapy, specifically its level of usage, cost, and accessibility. 
With the quick advancement of more gene editing therapies and the excitement 
surrounding it, it is critical that the scientific community works with professionals from 
various industries to determine when and where the introduction of gene editing therapy 
is ethical, fiscally responsible, scalable, and accessible. Interprofessional communication 
and collaboration will aid the direction of systematic decisions.  
Gene editing therapies can be life changing and germ line gene edits can have 
trans-generational impacts. Similarly, the responses to the advancement of gene editing 
therapy and systematic decisions on rules and regulations surrounding the use of 
CRISPR/Cas9 and other gene editing modalities will have large impacts on society. 
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